•
Dec 31, 2020

Molina Q4 2020 Earnings Report

Reported net income for the fourth quarter and year-end 2020 and introduced full year 2021 earnings guidance.

Key Takeaways

Molina Healthcare reported a net income of $34 million for Q4 2020, or $0.56 per diluted share. The company issued its full year 2021 earnings guidance, with premium revenue growth expected to be over 25% and adjusted EPS expected to be in the range of $12.50 - $13.00.

Total revenue increased 15% to $19.4 billion for the full year 2020 compared to 2019.

For the full year 2020, net income was $673 million, or $11.23 per diluted share, compared to net income of $737 million, or $11.47 per diluted share, for the full year 2019.

The Company issued its full year 2021 earnings guidance, with premium revenue growth expected to be over 25% and adjusted EPS expected to be in the range of $12.50 - $13.00.

Included in the Company’s guidance is the effect of the overhang from COVID and Medicare risk scores expected to soon abate.

Total Revenue
$5.24B
Previous year: $4.27B
+22.5%
EPS
-$0.51
Previous year: $2.73
-118.7%
Medicaid Membership
3.6M
Previous year: 2.96M
+21.8%
Medicare Membership
115K
Previous year: 101K
+13.9%
Marketplace Membership
318K
Previous year: 274K
+16.1%
Gross Profit
$587M
Previous year: $607M
-3.3%
Cash and Equivalents
$4.15B
Previous year: $2.45B
+69.4%
Free Cash Flow
$1.29B
Previous year: $2M
+64350.0%
Total Assets
$9.53B
Previous year: $6.79B
+40.4%

Molina

Molina

Forward Guidance

The Company issued its full year 2021 earnings guidance, with premium revenue growth expected to be over 25% and adjusted EPS expected to be in the range of $12.50 - $13.00.

Positive Outlook

  • Continued strong performance in Medicaid and Medicare;
  • Margin recovery and growth in the Marketplace business;
  • Accretion from the Magellan Complete Care businesses and the Kentucky and Passport installation; and,
  • The elimination of the Health Insurer Fee.
  • Included in the Company’s guidance is the effect of the overhang from COVID and Medicare risk scores expected to soon abate.

Challenges Ahead

  • A negative net effect of COVID due to a continuation of many of the risk-sharing corridors that existed in 2020 and the direct costs of COVID-related patient care;
  • Medicare risk scores;
  • Net pharmacy benefit carve-outs.
  • The Affinity acquisition, as the transaction has not yet closed; and,
  • The impact of potential Public Health Emergency extensions beyond mid-April 2021.